Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Melanoma 2Advanced Malignancies 2Urothelial Cancer 1Thyroid Neoplasms 1Solid Tumors, KRAS Mutation 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Prostatic Neoplasms 1Prostate Cancer Metastatic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Opioid-Related Disorders 1Lung Neoplasms 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Leiomyosarcoma 1KRAS p.G12C Mutant Advanced Solid Tumors 1Hematologic Neoplasms 1Healthy Adult Participants 1Glioma 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Cancer Pain 1

Interventions

Cyclophosphamide 31fludarabine 28Whole-Body Irradiation 18Mycophenolic Acid 18venetoclax 14Tacrolimus 14fludarabine phosphate 13Standard of Care 13Specimen Handling 10Practice Guidelines as Topic 10Melphalan 10Busulfan 10Sirolimus 9Thiotepa 8Interviews as Topic 8Azacitidine 8Educational Status 7trametinib 6Surveys and Questionnaires 6Methods 6Mesna 6Biopsy 6thymoglobulin 5Rituximab 5Magnetic Resonance Spectroscopy 5Filgrastim 5Early Intervention, Educational 5Behavior Therapy 5Antilymphocyte Serum 5Peripheral Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Midazolam × 1 year × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡